Risk stratification and prognosticators of acute myeloid leukemia with myelodysplasia-related changes patients undergoing allogeneic stem cell transplantation: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a distinct entity defined by the World Health Organization (WHO) in 2008, by the presence of multilineage dysplasia (MLD), and/or myelodysplastic syndrome (MDS)-related cytogenetics, and/or a history of MDS or MDS/myeloproliferative neoplasm (MPN) [1]. In the 2016 WHO classification, AML-MRC was preserved as a distinct entity, with some minor revisions in MDS-related cytogenetics [2]. A majority of the patients in studies reporting that the prognosis of AML-MRC was worse than that of AML-not otherwise specified (NOS) [3 –8] had undergone chemotherapy rather than allogeneic stem cell transplantation (allo-SCT).

Source: Biology of Blood and Marrow Transplantation - May 1, 2019 Category: Hematology Authors: Kaito Harada, Takaaki Konuma, Shinichiro Machida, Jinichi Mori, Jun Aoki, Naoyuki Uchida, Kazuteru Ohashi, Takahiro Fukuda, Masatsugu Tanaka, Kazuhiro Ikegame, Yukiyasu Ozawa, Koji Iwato, Tetsuya Eto, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Shing Source Type: research